Patents by Inventor Inder Bhamra

Inder Bhamra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES
    Publication number: 20260069571
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin domain receptor 2 (DDR2). The compounds are particularly useful in the treatment of cancer and fibrotic diseases.
    Type: Application
    Filed: November 3, 2022
    Publication date: March 12, 2026
    Inventors: Inder Bhamra, Clifford D. Jones, Ana Varela Rodriguez, Nicolas E.S. Guisot
  • PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER
    Publication number: 20260055102
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin domain receptor 2 (DDR2). The compounds are particularly useful in the treatment of cancer and fibrotic diseases.
    Type: Application
    Filed: August 22, 2023
    Publication date: February 26, 2026
    Inventors: Nicolas E.S. Guisot, Inder Bhamra, Clifford D. Jones, James Ryan, Michal S. Andra, Ana Varela Rodriguez, Camille Gignoux
  • N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway
    Patent number: 12202826
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: January 21, 2025
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1
    Publication number: 20240336592
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising novel isoquinolone compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin domain receptor 2 (DDR2). The compounds are particularly useful in the treatment of cancer and fibrotic diseases.
    Type: Application
    Filed: August 15, 2022
    Publication date: October 10, 2024
    Inventors: Inder Bhamra, Clifford D. Jones, Ana Varela Rodriguez
  • QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITORS
    Publication number: 20240287078
    Abstract: This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins. The compounds of the invention may therefore be used in treating conditions mediated by KRAS proteins. For example, the compounds may be used in treating cancer.
    Type: Application
    Filed: June 9, 2022
    Publication date: August 29, 2024
    Inventors: Clifford D. Jones, Inder Bhamra, James Ryan
  • PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS
    Publication number: 20240279241
    Abstract: This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins. The compounds of the invention may therefore be used in treating conditions mediated by KRAS proteins. For example, the compounds may be used in treating cancer.
    Type: Application
    Filed: May 27, 2022
    Publication date: August 22, 2024
    Inventors: Clifford D. Jones, Inder Bhamra
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20230365549
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: April 3, 2023
    Publication date: November 16, 2023
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
    Patent number: 11643408
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 9, 2023
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20230121489
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: August 29, 2022
    Publication date: April 20, 2023
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
    Patent number: 11459326
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: October 4, 2022
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20210046076
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: September 1, 2020
    Publication date: February 18, 2021
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20200407356
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 31, 2020
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
    Patent number: 10793560
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: RedX Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
    Patent number: 10793562
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 6, 2020
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20190144447
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 16, 2019
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
    Patent number: 10202375
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: February 12, 2019
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20180319788
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway
    Patent number: 10047079
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: August 14, 2018
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20170298062
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 19, 2017
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20170275276
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: October 8, 2015
    Publication date: September 28, 2017
    Applicant: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue